Y08262 is a potent and selective CBP bromodomain inhibitor. Y08262 selectively inhibits the CBP bromodomain with an IC 50 value of 73.1 nM. Y08262 can be used for the research of acute myeloid leukemia (AML).
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Histone Acetyltransferase | Products > Signaling Pathways > Epigenetic Reader Domain
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.